A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cogni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of psychiatry 1994-01, Vol.151 (1), p.126-129
Hauptverfasser:	FLICKER, C, FERRIS, S. H, KALKSTEIN, D, SERBY, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer Disease - psychology Biological and medical sciences Blood Pressure - drug effects Double-Blind Method Drug Administration Schedule Female Gangliosides - adverse effects Gangliosides - pharmacology Gangliosides - therapeutic use Humans Male Medical sciences Middle Aged Miscellaneous Nerve Growth Factors - physiology Neuropharmacology Neuropsychological Tests Pharmacology. Drug treatments Placebos Stimulation, Chemical Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.
ISSN:	0002-953X 1535-7228
DOI:	10.1176/ajp.151.1.126